GOLDILOX-T Trademark

Trademark Overview

On Tuesday, June 21, 2016, a trademark application was filed for GOLDILOX-T with the United States Patent and Trademark Office. The USPTO has given the GOLDILOX-T trademark a serial number of 79193069. The federal status of this trademark filing is CANCELLED - SECTION 71 as of Friday, January 12, 2024. This trademark is owned by Cartherics Pty Ltd. The GOLDILOX-T trademark is filed in the Pharmaceutical Products category with the following description:

Biological preparations for medical purposes for the treatment of cancer; biological preparations for pharmaceutical purposes for the treatment of cancer; biological preparations for medical use in biotechnology for the treatment of cancer; biological products for medical use, namely, Cytotoxic T cells with antigen receptor (TCR) specific for cancer plus a chimeric antigen receptor (CAR) specific for another cancer antigen; biological substances for medical use, namely, Cytotoxic T cells with antigen receptor (TCR) specific for cancer plus a chimeric antigen receptor (CAR) specific for another cancer antigen; therapeutic biological products for medical use, namely, Cytotoxic T cells with antigen receptor (TCR) specific for cancer plus a chimeric antigen receptor (CAR) specific for another cancer antigen
goldilox-t

General Information

Serial Number79193069
Word MarkGOLDILOX-T
Filing DateTuesday, June 21, 2016
Status709 - CANCELLED - SECTION 71
Status DateFriday, January 12, 2024
Registration Number5229982
Registration DateTuesday, June 27, 2017
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 11, 2017

Trademark Statements

Goods and ServicesBiological preparations for medical purposes for the treatment of cancer; biological preparations for pharmaceutical purposes for the treatment of cancer; biological preparations for medical use in biotechnology for the treatment of cancer; biological products for medical use, namely, Cytotoxic T cells with antigen receptor (TCR) specific for cancer plus a chimeric antigen receptor (CAR) specific for another cancer antigen; biological substances for medical use, namely, Cytotoxic T cells with antigen receptor (TCR) specific for cancer plus a chimeric antigen receptor (CAR) specific for another cancer antigen; therapeutic biological products for medical use, namely, Cytotoxic T cells with antigen receptor (TCR) specific for cancer plus a chimeric antigen receptor (CAR) specific for another cancer antigen

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status CodeF - NOT AVAILABLE
Class Status DateFriday, January 12, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCartherics Pty Ltd
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressArmadale Victoria 3143
AU
Party NameCartherics Pty Ltd
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressArmadale Victoria 3143
AU
Party NameCartherics Pty Ltd
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressArmadale Victoria 3143
AU

Trademark Events

Event DateEvent Description
Thursday, October 6, 2016SN ASSIGNED FOR SECT 66A APPL FROM IB
Tuesday, October 11, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, October 11, 2016ASSIGNED TO EXAMINER
Thursday, October 13, 2016NON-FINAL ACTION WRITTEN
Friday, October 14, 2016NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Saturday, October 15, 2016APPLICATION FILING RECEIPT MAILED
Friday, December 30, 2016NEW REPRESENTATIVE AT IB RECEIVED
Wednesday, November 2, 2016REFUSAL PROCESSED BY MPU
Wednesday, November 2, 2016NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Friday, November 18, 2016REFUSAL PROCESSED BY IB
Friday, January 20, 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, February 7, 2017ASSIGNED TO LIE
Wednesday, February 8, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, February 8, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, February 28, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, March 6, 2017LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, March 22, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, March 22, 2017NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, March 22, 2017NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Tuesday, April 11, 2017PUBLISHED FOR OPPOSITION
Tuesday, April 11, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 27, 2017REGISTERED-PRINCIPAL REGISTER
Wednesday, September 27, 2017FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Thursday, September 28, 2017FINAL DISPOSITION NOTICE SENT TO IB
Tuesday, March 22, 2022TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Saturday, April 8, 2017NOTIFICATION PROCESSED BY IB
Thursday, September 28, 2017FINAL DISPOSITION PROCESSED
Saturday, October 28, 2017FINAL DECISION TRANSACTION PROCESSED BY IB
Thursday, October 18, 2018NEW REPRESENTATIVE AT IB RECEIVED
Tuesday, March 22, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, March 22, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, March 22, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, June 27, 2022COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Friday, January 12, 2024CANCELLED SECTION 71
Saturday, September 14, 2024TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Monday, October 7, 2024TOTAL INVALIDATION PROCESSED BY THE IB
Saturday, September 14, 2024INVALIDATION PROCESSED
Monday, December 19, 2022NEW REPRESENTATIVE AT IB RECEIVED
Friday, September 13, 2024TOTAL INVALIDATION OF REG EXT PROTECTION CREATED

Related Keywords

goldilox antigen cancer receptor specific biological medical plus another chimeric cells